Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by Roth Capital to a “strong-buy” rating in a note issued to investors on Friday,Zacks.com reports.

RVPH has been the subject of several other reports. EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd. Roth Mkm began coverage on Reviva Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Friday. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $11.25.

Reviva Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:RVPH opened at $1.88 on Friday. The firm has a market cap of $62.87 million, a PE ratio of -1.69 and a beta of -0.12. The company’s 50 day moving average price is $1.56 and its two-hundred day moving average price is $1.29. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.83.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.